IPP Bureau
India becomes first country to approve STIMULAN Rapid Cure with antifungals
By IPP Bureau - November 26, 2025
Surgical site infections and antimicrobial resistance remain major challenges globally
Novartis scores FDA nod for game-changing SMA treatment
By IPP Bureau - November 26, 2025
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub
By IPP Bureau - November 25, 2025
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Brenntag to showcase latest pharma innovation at CPHI India 2025
By IPP Bureau - November 25, 2025
A key highlight will be Brenntag’s qualified amino acids portfolio
EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma
By IPP Bureau - November 25, 2025
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Eli Lilly to unveil major breast cancer data at SABCS 2025
By IPP Bureau - November 25, 2025
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Thermo Fisher opens two new centers in Hyderabad
By IPP Bureau - November 25, 2025
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025
By IPP Bureau - November 25, 2025
Jaypirca is making waves in the fight against B-cell malignancies
Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder
By IPP Bureau - November 25, 2025
Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials
By IPP Bureau - November 25, 2025
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Abbott issues urgent correction for FreeStyle Libre 3 Sensors amid safety concerns
By IPP Bureau - November 25, 2025
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Solventum to acquire Acera Surgical in $725 million deal
By IPP Bureau - November 25, 2025
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Sorcero scores $42.5M series B to supercharge AI-Driven life sciences insights
By IPP Bureau - November 25, 2025
Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership
By IPP Bureau - November 25, 2025
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Abbott to acquire Exact Sciences for $21 billion
By IPP Bureau - November 25, 2025
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
